CNAT - A Closer Look: Conatus' Prospects With Severe Portal Hypertension Post Subgroup Analysis
Preface
Within my exclusive marketplace, The Formula, I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.).
Conatus (CNAT), in collaboration with Novartis (NVS), is developing emricasan for a variety of metabolic disorders.
Severe Portal Hypertension
Pathophysiology
Portal hypertension is an increase of blood pressure within the portal vein, which carries blood from our digestive tract to the liver. It is a common result of liver disease (cirrhosis). The damaged liver results in increased scar tissue. The scar tissue makes it more difficult for